# Hitting Two Birds With One Stone: Dual Modulation of Brain Carbonic Anhydrases and Histone Deacetylases Boosts Memory Consolidation

## TL;DR

This study introduces a new drug approach that improves memory by targeting two brain enzymes at once, using lower doses than traditional treatments.

## Contribution

The paper presents a novel dual-target molecular design that activates carbonic anhydrase and inhibits histone deacetylase to enhance memory consolidation.

## Key findings

- The compounds significantly improved memory consolidation in a novel object recognition test.
- They achieved this at doses 10 times lower than single-target reference compounds.
- The dual modulation of CA and HDAC shows promise for treating cognitive impairments in various disorders.

## Abstract

Cognitive impairments, characterized by deficits in one or more cognitive domains, are common in several pathological conditions but remain inadequately addressed by available pharmacological treatments. Given the complexity and multifaceted mechanisms underpinning these deficits, multi‐targeted directed ligands are emerging as promising strategies for developing more effective therapies. In this study, we reported the design, synthesis as well as In Vitro and Ex Vivo assessment of prototypic molecular scaffolds that activate the carbonic anhydrase (CA; EC 4.2.1.1) and inhibit the histone deacetylase (HDAC; EC 3.5.1.98) metalloenzymes. By using the novel object recognition paradigm, we found that these compounds significantly enhanced memory consolidation at doses 10 times lower than single‐target reference compounds. Taken together, these results suggest that the dual modulation of CA and HDAC activities by means of a single hybrid molecular entity represents an innovative approach for the management of cognitive symptoms associated with neurodegenerative, neurodevelopment, and psychiatric disorders.

Multitarget‐directed ligands were obtained by merging the carbonic anhydrase (CA) activating histamine with the selective histone deacetylase (HDAC) inhibitor of the benzamide type. The derivatives showed good CA activation and HDAC inhibition In Vitro and Ex Vivo, and enhanced recognition memory consolidation at doses 10‐fold lower than the single reference drugs.